NR AVNH
AU de Pedro Cuesta,J.; Glatzel,M.; Almazan,J.; Stoeck,K.; Mellina,V.; Puopolo,M.; Pocchiari,M.; Zerr,I.; Kretzschmar,H.A.; Brandel,J.P.; Delasnerie-Laupretre,N.; Alperovitch,A.; van Duijn,C.; Sanchez-Juan,P.; Collins,S.J.; Lewis,V.; Jansen,G.H.; Coulthart,M.B.; Gelpi,E.; Budka,H.; Mitrova,E.
TI Human transmissible spongiform encephalopathies in eleven countries: diagnostic pattern across time, 1993-2002.
QU BMC Public Health 2006; 6: 278
PT comparative study; journal article; research support, non-u.s. gov't
AB BACKGROUND: The objective of this study was to describe the diagnostic panorama of human transmissible spongiform encephalopathies across 11 countries. METHODS: From data collected for surveillance purposes, we describe annual proportions of deaths due to different human transmissible spongiform encephalopathies in eleven EUROCJD-consortium countries over the period 1993-2002, as well as variations in the use of diagnostic tests. Using logistic models we quantified international differences and changes across time. RESULTS: In general, pre-mortem use of diagnostic investigations increased with time. International differences in pathological confirmation of sporadic Creutzfeldt-Jakob disease, stable over time, were evident. Compared to their counterparts, some countries displayed remarkable patterns, such as: 1) the high proportion, increasing with time, of variant Creutzfeldt-Jakob disease in the United Kingdom, (OR 607.99 95% CI 84.72-4363.40), and France (OR 18.35, 95% CI 2.20-152.83); 2) high, decreasing proportions of iatrogenic Creutzfeldt-Jakob disease in France, (OR 5.81 95% CI 4.09-8.24), and the United Kingdom, (OR 1.54 95% CI 1.03-2.30); and, 3) high and stable ratios of genetic forms in Slovakia (OR 21.82 95% CI 12.42-38.33) and Italy (OR 2.12 95% CI 1.69-2.68). CONCLUSION: Considerable international variation in aetiological subtypes of human transmissible spongiform encephalopathies was evident over the observation period. With the exception of variant Creutzfeldt-Jakob disease and iatrogenic Creutzfeldt-Jakob disease in France and the United Kingdom, these differences persisted across time.
MH Australia/epidemiology; Canada/epidemiology; Creutzfeldt-Jakob Syndrome/*diagnosis/*mortality/transmission; Cross-Cultural Comparison; Electroencephalography; Europe; France/epidemiology; Genotype; Great Britain/epidemiology; Humans; Iatrogenic Disease/epidemiology; Internationality; Italy/epidemiology; Magnetic Resonance Imaging; Population Surveillance/*methods; Prions/*genetics/pathogenicity; Registries; Slovakia/epidemiology; Time
AD Jesus de Pedro-Cuesta (jpedro@isciii.es), Javier Almazan (jalmazan@isciii.es), Instituto de Salud Carlos III, Centro Nacional de Epidemiologia, Departamento de Epidemiologia Aplicada, Calle Sinesio Delgado 6, 28029, Madrid, Spain; Markus Glatzel (m.glatzel@uke.uni-hamburg.de), Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, D-20246 Hamburg, Germany; Katharina Stoeck (Katarina.Stoeck@usz.ch), Institute of Neuropathology, University Hospital Zürich, Switzerland; Vittorio Mellina (vimelli@iss.it), Maria Puopolo (mpuopolo@iss.it), Maurizio Pocchiari (pocchia@iss.it), Registry of Creutzfeldt-Jakob disease, - Department of Cell.Biology and Neurosciences, Istituto Superiore di Sanita, Viale Regina Elena 299, 00161 Rome, Italy; Inga Zerr (ingazerr@med.uni-goettingen.de), Department of Neurology, Georg-August-Universität Göttingen, Robert-Koch Strasse 40, 37075 Göttingen, Germany; Hans A Kretzschmar (hans.kretzschmar@inp.med.uni-muenchen.de), Department of Neuropathology, Ludwig-Maximilian University, Munich, Germany; Jean-Philippe Brandel (jean-philippe.brandel@psl.ap-hop-paris.fr), Nicole Delasnerie-Laupretre (laupretre@chups.jussieu.fr), Annick Alperovitch (annick.alperovitch@chups.jussieu.fr), U.708 INSERM, Hopital de la Salpetriere, 75651 Paris, Cedex 13, France; Cornelia van Duijn (c.vanduijn@erasmusmc.nl), Pascual Sanchez-Juan (p.sanchezjuan@erasmusmc.nl), Department of Epidemiology and Biostatistics, Erasmus MC, PO Box 1738, 3000 DR Rotterdam, The Netherlands; Steven Collins (stevenjc@unimelb.edu.au), Victoria Lewis (vlewis@unimelb.edu.au), Australian National Creutzfeldt-Jakob disease Registry, Department of Pathology, The University of Melbourne, Parkville, Australia; Gerard H Jansen (gerard_jansen@phac-aspc.gc.ca), Michael B Coulthart (mike_coulthart@phac-aspc.gc.ca), CJD Surveillance System, Division of Host Genetics and Prion Diseases, Public Health Agency of Canada, LCDC Building, AL 0601E2, Tunney's Pasture, Ottawa, Ontario, K1A 0L2, Canada; Ellen Gelpi (elena.gelpi-mantius@meduniwien.ac.at), Herbert Budka (herbert.budka@meduniwien.ac.at), Institute of Neurology, Medical University of Vienna, and Austrian Reference Centre for Human Prion Diseases, AKH 4J, A-1097 Vienna, Austria; Eva Mitrova (eva.mitrova@szu.sk), Research base of Slovak Medical University, Bratislava, Slovakia
SP englisch
PO England